Comparison of insulin resistance, metabolic syndrome and adiponectin in overweight bipolar patients taking sodium valproate and controls

Australian and New Zealand Journal of Psychiatry

Volumn 43, Issue 1, 2009, Pages 53-60

  Elmslie, Jane L ^a   Porter, Richard J ^a   Joyce, Peter R ^a   Hunt, Penelope J ^a   Shand, Brett I ^b   Scott, Russell S ^b  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b CHRISTCHURCH HOSPITAL   (New Zealand)

Author keywords

Adiponectin; Bipolar disorder; Body mass index; Insulin resistance; Sodium valproate; The metabolic syndrome

Indexed keywords

ADIPONECTIN; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; VALPROIC ACID;

ADULT; AGE; ARTICLE; BIPOLAR DISORDER; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DIET RESTRICTION; DYSLIPIDEMIA; ETHNICITY; FEMALE; GENDER; HUMAN; HYPERGLYCEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; METABOLIC SYNDROME X; OBESITY; WEIGHT GAIN;

ADIPONECTIN; ADULT; ANTICONVULSANTS; ANTIPSYCHOTIC AGENTS; BIPOLAR DISORDER; BODY MASS INDEX; COMORBIDITY; CROSS-SECTIONAL STUDIES; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; FEMALE; HUMANS; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE AGED; OBESITY; OVERWEIGHT; RISK FACTORS; VALPROIC ACID; WAIST-HIP RATIO;

EID: 58049083737     PISSN: 00048674     EISSN: 14401614     Source Type: Journal    
DOI: 10.1080/00048670802534341     Document Type: Article

References (56)

1. Eckel, RH, Grundy, SM and Zimmet, PZ. (2005) The metabolic syndrome. Lancet, 365:9468, pp. 1415-1428.
2. Kong, AP, Chan, NN and Chan, JC. (2006) The role of adipocytokines and neurohormonal dysregulation in metabolic syndrome. Curr Diabetes Rev, 2, pp. 397-407.
3. Takemura, Y., Walsh, K. and Ouchi, N. (2007) Adiponectin and cardiovascular inflammatory responses. Curr Atheroscler Rep, 9, pp. 238-243.
4. Steffens, S. and Mach, F. (2008) Adiponectin and adaptive immunity: linking the bridge from obesity to atherogenesis. Circ Res, 102, pp. 140-142.
5. Despres, JP. (2006) Is visceral obesity the cause of the metabolic syndrome?. Ann Med, 38, pp. 52-63.
6. Ford, ES, Giles, WH and Dietz, WH. (2002) Prevalence of the metabolic syndrome among US adults: Findings from the third National Health and Nutrition Examination Survey. JAMA, 287, pp. 356-359.
7. Simmons, D. and Thompson, CF. (2004) Prevalence of the metabolic syndrome among adult New Zealanders of Polynesian and European descent. Diabetes Care, 27, pp. 3002-3004.
8. Fagiolini, A., Frank, E., Scott, JA, Turkin, S. and Kupfer, DJ. (2005) Metabolic syndrome in bipolar disorder: Findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord, 7, pp. 424-430.
9. Kilbourne, AM, Cornelius, JR Han, X. et al. (2004) Burden of general medical conditions among individuals with bipolar disorder. Bipolar Disord, 6, pp. 368-373.
10. Thompson, WK, Kupfer, DJ, Fagiolini, A., Scott, JA and Frank, E. (2006) Prevalence and clinical correlates of medical comorbidities in patients with bipolar I disorder: Analysis of acute-phase data from a randomized controlled trial. J Clin Psychiatry, 67, pp. 783-788.
11. Morriss, R. and Mohammed, FA. (2005) Metabolism, lifestyle and bipolar affective disorder. J Psychopharmacol, 19, pp. 94-101.
12. Elmslie, J., Mann, J., Silverstone, T., Williams, S. and Romans, S. (2001) Determinants of overweight and obesity in patients with bipolar disorder. J Clin Psychiatry, 62, pp. 486-491.
13. Mann, JI. (2006) Nutrition recommendations for the treatment and prevention of type 2 diabetes and the metabolic syndrome: An evidenced-based review. Nutr Rev, 64, pp. 422-427.
14. Guo, JJ, Keck Jr, PE Corey-Lisle, PK et al. (2006) Risk of diabetes mellitus associated with atypical antipsychotic use among patients with bipolar disorder: A retrospective, population-based, case-control study. J Clin Psychiatry, 67, pp. 1055-1061.
15. Taylor, V. and MacQueen, G. (2006) Associations between bipolar disorder and metabolic syndrome: A review. J Clin Psychiatry, 67, pp. 1034-1041.
16. Regenold, WT, Thapar, RK, Marano, C., Gavirneni, S. and Kondapavuluru, PV. (2002) Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord, 70, pp. 19-26.
17. Pylvanen, V., Pakarinen, A., Knip, M. and Isojarvi, J. (2006) Insulin-related metabolic changes during treatment with valproate in patients with epilepsy. Epilepsy Behav, 8, pp. 643-648.
18. Verrotti, A., di Corcia, G, Salladini, C., Trotta, D., Morgese, G. and Chiarelli, F. (2003) Serum insulin and leptin levels and valproate-associated obesity. Epilepsia, 44, p. 1606.
19. Breum, L., Astrup, A. Gram, L. et al. (1992) Metabolic changes during treatment with valproate in humans: Implication for untoward weight gain. Metabolism, 41, pp. 666-670.
20. Pylvanen, V., Pakarinen, A., Knip, M. and Isojarvi, J. (2006) Characterization of insulin secretion in valproate-treated patients with epilepsy. Epilepsia, 47, pp. 1460-1464.
21. Newcomer, JW. (2005) Second-generation (atypical) antipsychotics and metabolic effects: A comprehensive literature review. CNS Drugs, 19, pp. 1-93.
22. Elmslie, JL, Porter, RJ, Joyce, PR, Hunt, PJ and Mann, JI. (2006) Carnitine does not improve weight loss outcomes in valproate-treated bipolar patients consuming an energy-restricted, low-fat diet. Bipolar Disord, 8:5, pp. 503-507.
23. Shand, BI, Scott, RS, Elder, PA and George, PM. (2003) Plasma adiponectin in overweight, nondiabetic individuals with or without insulin resistance. Diabetes Obes Metab, 5, pp. 349-353.
24. First, M., Spitzer, R., Gibbon, M. and Williams, J. (1998) Structured Clinical Interview for DSM-1V Axis 1 Disorders. SCID-1/P, version 2.0, New York State Psychiatric Institute, Biometrics Research Department, NY
25. Young, RC, Biggs, JT, Ziegler, VE and Meyer, DA. (1978) A rating scale for mania: Reliability, validity and sensitivity. Br J Psychiatry, 133, pp. 429-435.
26. Montgomery, SA and Asberg, M. (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry, 134, pp. 382-389.
27. Friedewald, WT, Levy, RI and Fredrickson, DS. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem, 18, pp. 499-502.
28. Matthews, DR, Hosker, JP, Rudenski, AS, Naylor, BA, Treacher, DF and Turner, RC. (1985) Homeostasis model assessment: Insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 28, pp. 412-419.
29. (2001) JAMA, 285, pp. 2486-2497.
30. Rasgon, NL, Altshuler, LL Fairbanks, L. et al. (2005) Reproductive function and risk for PCOS in women treated for bipolar disorder. Bipolar Disord, 7, pp. 246-259.
31. Luef, G., Abraham, I. Hoppichler, F. et al. (2002) Increase in postprandial serum insulin levels in epileptic patients with valproic acid therapy. Metabolism, 51, pp. 1274-1278.
32. Verrotti, A., Basciani, F., Morresi, S., de Martino, M., Morgese, G. and Chiarelli, F. (1999) Serum leptin changes in epileptic patients who gain weight after therapy with valproic acid. Neurology, 53, pp. 230-232.
33. Verrotti, A., Basciani, F., De Simone, M., Trotta, D., Morgese, G. and Chiarelli, F. (2002) Insulin resistance in epileptic girls who gain weight after therapy with valproic acid. J Child Neurol, 17, pp. 265-268.
34. Grant, BF, Hasin, DS, Chou, SP, Stinson, FS and Dawson, DA. (2004) Nicotine dependence and psychiatric disorders in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry, 61, pp. 1107-1115.
35. Dzien, A., Dzien-Bischinger, C., Hoppichler, F. and Lechleitner, M. (2004) The metabolic syndrome as a link between smoking and cardiovascular disease. Diabetes Obes Metab, 6, pp. 127-132.
36. Ishizaka, N., Ishizaka, Y., Toda, E., Hashimoto, H., Nagai, R. and Yamakado, M. (2005) Association between cigarette smoking, metabolic syndrome, and carotid arteriosclerosis in Japanese individuals. Atherosclerosis, 181, pp. 381-388.
37. Wild, SH and Byrne, CD. (2006) ABC of obesity. Risk factors for diabetes and coronary heart disease. BMJ, 333:7576, pp. 1009-1011.
38. Takefuji, S., Yatsuya, H. Tamakoshi, K. et al. (2007) Smoking status and adiponectin in healthy Japanese men and women. Prev Med, 45, pp. 471-475.
39. Citrome, L., Jaffe, A., Levine, J., Allingham, B. and Robinson, J. (2004) Relationship between antipsychotic medication treatment and new cases of diabetes among psychiatric inpatients. Psychiatr Serv, 55, pp. 1006-1013.
40. Lamberti, JS, Olson, D. Crilly, JF et al. (2006) Prevalence of the metabolic syndrome among patients receiving clozapine. Am J Psychiatry, 163, pp. 1273-1276.
41. Fried, SK and Rao, SP. (2003) Sugars, hypertriglyceridemia, and cardiovascular disease. Am J Clin Nutr, 78, pp. 873S-80S.
42. Van Gaal, LF, Mertens, IL and De Block, CE. (2006) Mechanisms linking obesity with cardiovascular disease. Nature, 444:7121, pp. 875-880.
43. Brown, ES. (2005) Bipolar disorder and substance abuse. Psychiatr Clin North Am, 28, pp. 415-425.
44. Isojarvi, J., Rattya, J. Myllyla, V. et al. (1998) Valproate, lamotrigine and insulin-mediated risks in women with epilepsy. Ann Neurol, 43, pp. 446-451.
45. Nikolaos, T., Stylianos, G. Chryssoula, N. et al. (2004) The effect of long-term antiepileptic treatment on serum cholesterol (TC, HDL, LDL) and triglyceride levels in adult epileptic patients on monotherapy. Med Sci Monit, 10, p. MT50.
46. Kim, JY and Lee, HW. (2007) Metabolic and hormonal disturbances in women with epilepsy on antiepileptic drug monotherapy. Epilepsia, 48, pp. 1366-1370.
47. Barter, P., McPherson, YR Song, K. et al. (2007) Serum insulin and inflammatory markers in overweight individuals with and without dyslipidemia. J Clin Endocrinol Metab, 92, pp. 2041-2045.
48. Pi-Sunyer, FX. (2006) The relation of adipose tissue to cardiometabolic risk. Clin Cornerstone, 8, pp. S14-S23.
49. Loos, RJ, Ruchat, S., Rankinen, T., Tremblay, A., Perusse, L. and Bouchard, C. (2007) Adiponectin and adiponectin receptor gene variants in relation to resting metabolic rate, respiratory quotient, and adiposity-related phenotypes in the Quebec Family Study. Am J Clin Nutr, 85, pp. 26-34.
50. Narita, K., Murata, T., Takahashi, T., Kosaka, H., Omata, N. and Wada, Y. (2006) Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy. Prog Neuropsychopharmacol Biol Psychiatry, 30, pp. 1159-1162.
51. Cohn, TA, Remington, G., Zipursky, RB, Azad, A., Connolly, P. and Wolever, TM. (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: A preliminary report. Can J Psychiatry, 51, pp. 382-386.
52. Togo, T., Kojima, K. Shoji, M. et al. (2004) Serum adiponectin concentrations during treatment with olanzapine or risperidone: A pilot study. Int Clin Psychopharmacol, 19, pp. 37-40.
53. Richards, AA, Hickman, IJ Wang, AY et al. (2006) Olanzapine treatment is associated with reduced high molecular weight adiponectin in serum: A potential mechanism for olanzapine-induced insulin resistance in patients with schizophrenia. J Clin Psychopharmacol, 26, pp. 232-237.
54. Cooper, GD, Pickavance, LC, Wilding, JP, Harrold, JA, Halford, JC and Goudie, AJ. (2007) Effects of olanzapine in male rats: Enhanced adiposity in the absence of hyperphagia, weight gain or metabolic abnormalities. J Psychopharmacol, 21, pp. 405-413.
55. Greco, R., Latini, G., Chiarelli, F., Iannetti, P. and Verrotti, A. (2005) Leptin, ghrelin, and adiponectin in epileptic patients treated with valproic acid. Neurology, 65, pp. 1808-1809.
56. Qiao, L., Schaack, J. and Shao, J. (2006) Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology, 147, pp. 865-874.